Home  |  Contact

UniProtKB/Swiss-Prot P20823: Variant p.Gln250Pro

Hepatocyte nuclear factor 1-alpha
Gene: HNF1A
Variant information

Variant position:  250
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  US
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glutamine (Q) to Proline (P) at position 250 (Q250P, p.Gln250Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (Q) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In a hepatocellular carcinoma sample; somatic mutation.
Any additional useful information about the variant.



Sequence information

Variant position:  250
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  631
The length of the canonical sequence.

Location on the sequence:   ETLVEECNRAECIQRGVSPS  Q AQGLGSNLVTEVRVYNWFAN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFAN

Mouse                         ETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFAN

Rat                           ETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFAN

Chicken                       EALVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFAN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 631 Hepatocyte nuclear factor 1-alpha
DNA binding 199 – 279 Homeobox; HNF1-type
Modified residue 247 – 247 Phosphoserine
Alternative sequence 120 – 631 Missing. In isoform 8.
Alternative sequence 176 – 278 QFTHAGQGGLIEEPTGDELPTKKGRRNRFKWGPASQQILFQAYERQKNPSKEERETLVEECNRAECIQRGVSPSQAQGLGSNLVTEVRVYNWFANRRKEEAFR -> RRNASREGCPHHRHRGWAPTSSRRCVSTTGLPTGAKKKPSGTSWPWTRTAGPPQGQARDLRCPLTAPLACLHLPSPPVRSTVCAMDSLRPVRLQKYPQAAAVP. In isoform 4.
Alternative sequence 248 – 631 Missing. In isoform 5.
Mutagenesis 246 – 246 V -> D. Reduces transcription activation by 75%.
Mutagenesis 257 – 257 N -> W. Reduces transcription activation by 70%.


Literature citations

Bi-allelic inactivation of TCF1 in hepatic adenomas.
Bluteau O.; Jeannot E.; Bioulac-Sage P.; Marques J.M.; Blanc J.-F.; Bui H.; Beaudoin J.-C.; Franco D.; Balabaud C.; Laurent-Puig P.; Zucman-Rossi J.;
Nat. Genet. 32:312-315(2002)
Cited for: INVOLVEMENT IN HEPATIC ADENOMAS; VARIANTS TYR-127; CYS-165; CYS-206; LEU-206; SER-237; GLY-244; PRO-250; CYS-268; GLU-273; SER-574 AND GLN-583;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.